The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of olutasidenib in relapsed/refractory acute myeloid leukemia: Outcomes by number of prior treatment regimens.
 
Eunice Wang
Consulting or Advisory Role - Abbvie; Blueprint Medicines; Celgene/Bristol-Myers Squibb; CTI BioPharma Corp; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Immunogen; Johnson & Johnson/Janssen; Kite/Gilead; Kura Oncology; Novartis; Qiagen; Rigel; Ryvu Therapeutics; Schrodinger; SERVIER; Stemline Therapeutics; Sumitomo Pharma Oncology; Syndax; Takeda
Speakers' Bureau - Astellas Pharma; Daiichi Sankyo/UCB Japan; DAVA Pharmaceuticals; Pfizer
Other Relationship - Abbvie/Genentech; Gilead Sciences; Gilead Sciences; UpToDate
 
Jorge Cortes
Consulting or Advisory Role - Bio-Path Holdings, Inc; Enliven Therapeutics; Gilead Sciences; Novartis; Pfizer; Rigel; Sun Pharma; Syndax; Takeda; Terns Pharmaceuticals
Research Funding - Abbvie/Genentech (Inst); Actuate Therapeutics (Inst); Bio-Path Holdings, Inc (Inst); Cyto Agents (Inst); Jazz Pharmaceuticals (Inst); Kuro Oncology (Inst); Novartis (Inst); Pfizer (Inst); Sellas Life Sciences (Inst); Sun Pharma (Inst)
 
Andrew Wei
Honoraria - Abbvie/Genentech; Aculeus (Inst); Amgen; Astellas Pharma; AstraZeneca; BeiGene; Celgene; Gilead/Forty Seven; Janssen Oncology; Novartis; Pfizer; SERVIER; Syndax (Inst)
Consulting or Advisory Role - Abbvie/Genentech; Amgen; Astellas Pharma; AstraZeneca; BeiGene; Janssen; Novartis; Pfizer; SERVIER; Syndax (Inst)
Speakers' Bureau - Abbvie/Genentech; Astex Pharmaceuticals; Celgene/Bristol-Myers Squibb; Novartis; SERVIER
Research Funding - Abbvie (Inst); Novartis (Inst); Servier (Inst)
Patents, Royalties, Other Intellectual Property - AW is a former employee of the Walter and Eliza Hall Institute which receives milestone and royalty payments related to venetoclax, and is eligible for benefits related to these payments. AW receives payments from WEHI related to venetoclax
 
Stéphane De Botton
Honoraria - Abbvie; Astellas Pharma; Bristol-Myers Squibb; Jazz Pharmaceuticals; Servier
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Servier; Syndax
Speakers' Bureau - AbbVie; Astellas Pharma; Bristol Myers Squibb Foundation; Jazz Pharmaceuticals; Servier
Research Funding - Auron Therapeutics (Inst); Forma Therapeutics (Inst)
Travel, Accommodations, Expenses - AbbVie; Servier
 
Antonio Curti
Consulting or Advisory Role - AbbVie; Jazz Pharmaceuticals; Menarini; Novartis; Pfizer; SERVIER
 
Pau Montesinos
Consulting or Advisory Role - Abbvie; Daiichi Sankyo; Jazz Pharmaceuticals; Otsuka; Pfizer; SERVIER
Speakers' Bureau - Celgene; Daiichi Sankyo; Otsuka
Research Funding - Abbvie (Inst); Celgene (Inst); Daiichi Sankyo Europe GmbH (Inst); Janssen-Cilag (Inst); Pfizer (Inst); Servier (Inst)
Travel, Accommodations, Expenses - Amgen
 
Karen Yee
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Jazz Pharmaceuticals; Novartis; Pfizer; Roche; Shattuck Labs; Taiho Oncology; Takeda
Research Funding - Astex Pharmaceuticals; Forma Therapeutics; Genentech; Geron; Gilead Sciences; Janssen; Roche
 
Joseph Jurcic
Consulting or Advisory Role - Incyte; Rigel; Syros Pharmaceuticals
Research Funding - Blueprint Medicines; Bristol Myers Squibb Foundation; Forma Therapeutics; Kura Oncology; Seattle/Genetics/Pfizer; Sumitomo Dainippon Pharma
 
William Donnellan
No Relationships to Disclose
 
Jay Yang
Research Funding - Jansssen; Pfizer; PureTech
 
Brian Jonas
Consulting or Advisory Role - Abbvie; BMS; Gilead Sciences; Kura Oncology; Rigel; Schrodinger; Syndax; Treadwell Therapeutics
Research Funding - Abbvie (Inst); Amgen (Inst); Aptose Biosciences (Inst); AROG (Inst); Biomea Fusion (Inst); BMS (Inst); Celgene (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Glycomimetics (Inst); Hanmi (Inst); Immune-Onc Therapeutics (Inst); Jazz Pharmaceuticals (Inst); Kymera (Inst); Loxo (Inst); Pfizer (Inst); Pharmacyclics (Inst); Treadwell Therapeutics (Inst)
Travel, Accommodations, Expenses - Rigel
Other Relationship - Gilead Sciences
 
Aaron Sheppard
Employment - Rigel
Stock and Other Ownership Interests - Rigel
 
Hua Tian
Employment - Rigel
Stock and Other Ownership Interests - Rigel
 
Justin Watts
Consulting or Advisory Role - Aptose Biosciences; Astellas Pharma; Celgene/Bristol-Myers Squib; Daiichi Sankyo; Genentech; Rafael Pharmaceuticals; Reven Pharmaceuticals; Rigel; SERVIER; Takeda
Research Funding - Immune System Key; Takeda